menu
    • menu

    Company profile for Nimbus Therapeutics

    NEW Drugs in Dev: 6
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (USA). With its breakthrough computational chemistry platform, enabled through its privileged partnership with co-founder, Schrödinger, Inc., Nimbus is pioneering the application of computational chemistry to design treatments for substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-in...
    Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (USA). With its breakthrough computational chemistry platform, enabled through its privileged partnership with co-founder, Schrödinger, Inc., Nimbus is pioneering the application of computational chemistry to design treatments for substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-inflammatory disorders reflects the mechanistic relationship between these disorders, and Nimbus’ ability to rapidly tackle well validated targets as well as those that have proven intractable to the approaches.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nimbus TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    130 Prospect Street, Suite 301 Cambridge, MA 02139
    Telephone
    Telephone
    857-999-2009
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nimbustx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nimbus-therapeutics/?report%2Esuccess=KJ_KkFGTDCfMt-A7wV3Fn9Yvgwr02Kd6AZHGx4bQCDiP6-2rfP2oxyVoEQiPrcAQ7Bf
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/NimbusTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nimbus Therapeutics To Unveil SIK2 Inhibitors Data At ECCO
    Nimbus Therapeutics To Unveil SIK2 Inhibitors Data At ECCO

    17 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260217678330/en/Nimbus-Therapeutics-to-Present-Preclinical-and-Translational-Data-on-Novel-SIK2-Inhibitors-at-21st-Congress-of-European-Crohns-and-Colitis-Organisation-ECCO

    BUSINESSWIRE
    17 Feb 2026
    Share Share
    Lilly Returns To Nimbus In $1.3B Deal To Create Oral Obesity Med
    Lilly Returns To Nimbus In $1.3B Deal To Create Oral Obesity Med

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260106883316/en/Nimbus-Therapeutics-Announces-Research-Collaboration-and-License-Agreement-with-Lilly-for-Novel-Oral-Obesity-Treatment

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    Nimbus Therapeutics Completes Dose Escalation In Phase 1/2 Trial
    Nimbus Therapeutics Completes Dose Escalation In Phase 1/2 Trial

    19 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-19/nimbus-therapeutics-announces-completion-of-dose-escalation-in-phase-12-clinical-trial-of-ndi-21921

    PHARMIWEB
    19 Dec 2025
    Share Share
    Nimbus Therapeutics Starts First-in-Human Trial with NDI-219216
    Nimbus Therapeutics Starts First-in-Human Trial with NDI-219216

    25 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250425944016/en/Nimbus-Therapeutics-Announces-Initiation-of-First-in-Human-Clinical-Trial-with-NDI-219216-Novel-WRN-Inhibitor-for-MSI-H-Tumors

    BUSINESSWIRE
    25 Apr 2025
    Share Share
    Nimbus Therapeutics Appoints Abbas as Chief Executive Officer
    Nimbus Therapeutics Appoints Abbas as Chief Executive Officer

    07 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250307658905/en

    BUSINESSWIRE
    07 Mar 2025
    Share Share
    Nimbus Therapeutics Achieves Milestone in Collaboration with Lilly
    Nimbus Therapeutics Achieves Milestone in Collaboration with Lilly

    25 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250225848997/en

    BUSINESSWIRE
    25 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search